HDL-C in Cardiac Syndrome X

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver[10]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity[11]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk[12-14]. HDL-C also has anti- inflammatory and anti-oxidant activities[15,16]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils[17,18] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin[15].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases Angina Pectoris Angina, Unstable Arterial Occlusive Diseases Arteriosclerosis Chest Pain Coronary Artery Disease Coronary Disease Dyslipidemias Heart Diseases Inflammation Lipid Metabolism Disorders Metabolic Diseases Microvascular Angina Myocardial Ischaemia Myocardial Ischemia Neurologic Manifestations Nutritional and Metabolic Diseases Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Unstable Angina Vascular Diseases

Age range

47 year–58 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must be able to get exercise stress test
Must be able to have coronary angiography
Clinical diagnosis of typical anginaduring rest or effort
Abnormal test result for exercise ECG or myocardial perfusion scintigraphy
Must have of angiographically normal epicardial coronary arteries

Exclusion criteria

Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation
Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification)
Patients with heart failure (left ventricular ejection fraction <50%)
Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy
Patients with cardiac surgery
Patients with thyroid disease
Patients with anemia
Patients with pulmonary diseases
Patients with infectious diseases (locally or systemic)

Treatment and study plan

Primary outcomes

HDL-Cholesterol

Time frame: 6 MONTHS

HDL-Cholesterol <40 mg/dL(male) / < 50mg/dL(female) ==> low HDL-C
Cardiac Syndrome X

Time frame: 6 months

Patients who have typical anginal chest pain+ischaemic findings at exercise stress test/myocardial scintigraphy + normal epicardial coronaries at coronary angiography ==> Cardiac syndrome X
Inflammation

Time frame: 6 months

CRP > 2,98 mg/dL ==> systemic inflammation

Sponsors and collaborators

Lead sponsor

Bursa Yuksek Ihtisas Training and Research Hospital

Other Gov

Registry information

Official study title

HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X

Acronym: HIRICS-X

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2014
First posted: Mar 26, 2014
Registry last updated: Mar 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed